6th June 2022 | Pharma Updates
Sun Pharma intends to increase its field force in India by 10% this fiscal year
Sun Pharma plans to increase its field force in the domestic market by 10% in the current fiscal year in order to achieve the twin goals of brand focus and geographical expansion.
Uttarakhand STF raids illegal pharma units and busts an interstate fake drugs circle
In an overnight operation, the Uttarakhand Police Special Task Force (STF) busted an inter-state counterfeit medicine manufacturing ring and raided several illegal pharmaceutical factories across the state.
J&J and Pharmacyclics received CLL approval for Imbruvica
Imbruvica, a new drug developed by Johnson & Johnson and Pharmacyclics, has received the expanded approval required to move beyond a rare disease treatment and achieve the blockbuster status for which it was developed.
60L remdesivir remdesivir vials may be destroyed as demand falls
A year ago, relatives of Covid patients queued for hours at pharmacies for a single dose of remdesivir, but today, 60 lakh remdesivir vials are being destroyed as their expiry date approaches.
AstraZeneca & Daiichi's Enhertu's groundbreaking HER2-low study transform breast cancer treatment
AstraZeneca and Daiichi Sankyo could soon open up a brand-new breast cancer category and offer HER2-targeted therapy to many patients with what has traditionally been characterised as HER2-negative disease.
CStone and Pfizer announce NMPA approval of sugemalimab
CStone Pharmaceuticals & Pfizer announced that NMPA of China has approved sugemalimab for the treatment of patients with unresectable stage III non-small-cell lung cancer.
AbbVie on track to become largest pharmaceutical company by 2028
Despite facing one of the industry’s steepest patent cliffs, Abbvie is expected to surpass Roche to become the largest pharma company by prescription sales in 2028, as per Evaluate Pharma’s extended consensus forecasts.
